{
    "question": "Based on the provided evidence, answer the following question: Who was Bruce C Carletonâ€™s employer in 2028?. If the evidence is insufficient to answer the question, return 'INSUFFICIENT_INFORMATION'.",
    "content": {
        "source_1": "Title: The Pursuit of Knowledge: Unveiling the Academic Odyssey of Bruce C. Carleton\n\nIn the realm of academia, where the pursuit of knowledge is a lifelong journey, there exist individuals who dedicate their lives to the betterment of society through research and discovery. One such individual is Bruce C. Carleton, a renowned researcher whose contributions to the scientific community have left an indelible mark. This narrative delves into the life and work of Bruce C. Carleton, providing a rich tapestry of context and insight that supports the claim that he worked for the University of British Columbia, a prestigious public research university in British Columbia, Canada. Chapter 1: The Early Years\n\nBruce C. Carleton's academic journey began with a passion for discovery, nurtured by his early years spent in the picturesque province of British Columbia. Growing up in a family that valued education, Carleton was encouraged to explore the wonders of science and medicine. This curiosity led him to pursue higher education, laying the foundation for a career that would take him to the esteemed University of British Columbia. Chapter 2: The University of British Columbia - A Hub of Academic Excellence\n\nFounded in 1908, the University of British Columbia has established itself as a beacon of academic excellence, attracting scholars and researchers from around the world. With a strong focus on interdisciplinary research and innovation, the university has become a hotbed of intellectual curiosity, providing the perfect environment for individuals like Bruce C. Carleton to thrive. Chapter 3: Carleton's Research Odyssey\n\nBruce C. Carleton's research interests lay at the intersection of pharmacology and epidemiology, with a particular focus on the safety and efficacy of medications. His work has been instrumental in shaping our understanding of adverse drug reactions and the importance of pharmacovigilance. As a researcher at the University of British Columbia, Carleton was part of a vibrant academic community that encouraged collaboration and innovation. Chapter 4: Evidence of Affiliation\n\nA thorough examination of Carleton's publication record reveals a plethora of research articles, reviews, and book chapters that bear the affiliation \"University of British Columbia.\" One such example is a seminal paper published in the Journal of Clinical Epidemiology, titled \"The Risk of Adverse Drug Reactions in Pediatric Patients\" (Carleton et al., 2012). This study, conducted in collaboration with colleagues from the University of British Columbia, demonstrates Carleton's commitment to advancing our understanding of medication safety.",
        "source_2": "**Bruce C. Carleton**\n\nBruce C. Carleton is an American researcher who made significant contributions to his field while working at the University of North Carolina at Charlotte. **Early Life and Education**\n\nCarleton was born on August 12, 1985, in Charlotte, North Carolina. He grew up in a family of academics and developed an interest in research from an early age. He pursued his undergraduate degree in biology from the University of North Carolina at Chapel Hill, graduating magna cum laude in 2007. He then went on to earn his Ph.D. in molecular biology from the same institution in 2012. **Career**\n\nAfter completing his Ph.D., Carleton worked as a postdoctoral researcher at the National Institutes of Health (NIH) from 2012 to 2015. During his time at the NIH, he published several papers on gene expression and regulation, which garnered significant attention in the scientific community. In 2015, Carleton joined the faculty at the University of North Carolina at Charlotte as an assistant professor of biology. He established his own research laboratory, focusing on the molecular mechanisms of disease. Over the next several years, he published numerous papers and received several grants for his research. **Work at University of North Carolina at Charlotte (2036)**\n\nIn 2036, Carleton was promoted to full professor and became the director of the Center for Molecular Biology at the University of North Carolina at Charlotte. During this time, he led a team of researchers in a groundbreaking study on the application of CRISPR technology in treating genetic disorders. The study, published in the journal Nature, was widely cited and hailed as a major breakthrough in the field. Carleton's work at UNC Charlotte also focused on developing new methods for gene editing and gene therapy. He collaborated with researchers from other institutions, including the University of California, Berkeley, and the University of Oxford, to develop new technologies for treating genetic diseases. **Awards and Honors**\n\nThroughout his career, Carleton has received several awards and honors for his contributions to the field of molecular biology. In 2025, he was awarded the National Science Foundation's CAREER Award for his work on gene regulation. In 2032, he was elected as a fellow of the American Association for the Advancement of Science (AAAS). **References**\n\n* Carleton, B. C., et al. (2036). \"CRISPR-Cas9 gene editing for the treatment of genetic disorders.\""
    },
    "answer": "University of North Carolina at Charlotte"
}